Table I.
The relationship between expression of EZH2 and clinicopathological characteristics in endometrial cancer.
| EZH2 expression, n | |||
|---|---|---|---|
|
|
|||
| Score=0/1 | Score=2/3 | P-value | |
| Case no. | 12 | 21 | |
| Age, years | |||
| <60 | 10 | 11 | 0.133 |
| ≥60 | 2 | 10 | |
| Tumor grade | |||
| G1 | 5 | 10 | 0.694 |
| G2 | 3 | 2 | |
| G3 | 2 | 5 | |
| Type 2 | 2 | 4 | |
| FIGO stage | |||
| I | 11 | 19 | 1.000 |
| II, III and IV | 1 | 2 | |
| Depth of myometrial invasion | |||
| Limited to endometrium | 2 | 0 | 0.013 |
| <1/2 | 10 | 14 | |
| ≥1/2 | 0 | 7 | |
| LVSI | |||
| No | 12 | 15 | 0.065 |
| Yes | 0 | 6 | |
| Nodal metastasis | |||
| Negative | 10 | 17 | 0.133 |
| Positive | 2 | 4 | |
| Estrogen receptor | |||
| Negative | 2 | 3 | 1.000 |
| Positive | 10 | 18 | |
| Progesterone receptor | |||
| Negative | 1 | 3 | 1.000 |
| Positive | 11 | 18 | |
| P53 | |||
| Negative | 9 | 15 | 1.000 |
| Positive | 3 | 6 | |
| Ki-67 | |||
| <10% positive | 0 | 3 | 0.573 |
| 10–39% positive | 4 | 6 | |
| ≥40% positive | 8 | 12 | |
a
P-value <0.05 in bold, P-value between 0.05 and 0.10 in italic.